Novel Approaches to the Systemic Management of Uveal Melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-07-28

AUTHORS

Shaheer Khan, Richard D. Carvajal

ABSTRACT

Purpose of ReviewUveal melanoma is a distinct subtype of melanoma characterized by a unique biology and divergent response to immune therapies. In this review, we will discuss our current understanding of the pathophysiology of uveal melanoma, systemic treatment options for advanced disease, and potential future therapeutic directions.Recent FindingsAlthough treatment with single-agent checkpoint blockade has been generally disappointing, the results of combined checkpoint blockade are modestly more promising. Several alternative systemic therapeutic approaches have been or are currently being investigated, including two agents that have been taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor.SummaryTreatment of advanced uveal melanoma remains challenging, however, encouraging results from novel agents offer hope for improvement in the near future. More... »

PAGES

104

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11912-020-00965-0

DOI

http://dx.doi.org/10.1007/s11912-020-00965-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1129718020

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32725406


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uveal Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, 10032, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239585.0", 
          "name": [
            "Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, 10032, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khan", 
        "givenName": "Shaheer", 
        "id": "sg:person.016242444426.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016242444426.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Herbert Irving Comprehensive Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.516091.a", 
          "name": [
            "Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, 10032, New York, NY, USA", 
            "Herbert Irving Comprehensive Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00262-019-02352-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1116870697", 
          "https://doi.org/10.1007/s00262-019-02352-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.3549", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024973673", 
          "https://doi.org/10.1038/ng.3549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10555-018-9751-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106079214", 
          "https://doi.org/10.1007/s10555-018-9751-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature07586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018711414", 
          "https://doi.org/10.1038/nature07586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms10156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043043138", 
          "https://doi.org/10.1038/ncomms10156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10555-017-9663-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083859374", 
          "https://doi.org/10.1007/s10555-017-9663-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature09504", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001851540", 
          "https://doi.org/10.1038/nature09504"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1998.646", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036277436", 
          "https://doi.org/10.1038/bjc.1998.646"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41588-019-0440-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117623763", 
          "https://doi.org/10.1038/s41588-019-0440-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41467-018-04322-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103889258", 
          "https://doi.org/10.1038/s41467-018-04322-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00347-006-1350-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041025152", 
          "https://doi.org/10.1007/s00347-006-1350-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.2523", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004149711", 
          "https://doi.org/10.1038/ng.2523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-019-0800-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122559825", 
          "https://doi.org/10.1186/s40425-019-0800-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-07-28", 
    "datePublishedReg": "2020-07-28", 
    "description": "Purpose of ReviewUveal melanoma is a distinct subtype of melanoma characterized by a unique biology and divergent response to immune therapies. In this review, we will discuss our current understanding of the pathophysiology of uveal melanoma, systemic treatment options for advanced disease, and potential future therapeutic directions.Recent FindingsAlthough treatment with single-agent checkpoint blockade has been generally disappointing, the results of combined checkpoint blockade are modestly more promising. Several alternative systemic therapeutic approaches have been or are currently being investigated, including two agents that have been taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor.SummaryTreatment of advanced uveal melanoma remains challenging, however, encouraging results from novel agents offer hope for improvement in the near future.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11912-020-00965-0", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021174", 
        "issn": [
          "1523-3790", 
          "1534-6269"
        ], 
        "name": "Current Oncology Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "keywords": [
      "uveal melanoma", 
      "checkpoint blockade", 
      "potential future therapeutic directions", 
      "single-agent checkpoint blockade", 
      "systemic treatment options", 
      "advanced uveal melanoma", 
      "systemic therapeutic approaches", 
      "future therapeutic directions", 
      "advanced disease", 
      "immune therapy", 
      "treatment options", 
      "clinical trials", 
      "T cells", 
      "novel agents", 
      "therapeutic approaches", 
      "protein kinase C inhibitor", 
      "therapeutic directions", 
      "distinct subtypes", 
      "melanoma", 
      "kinase C inhibitor", 
      "systemic management", 
      "blockade", 
      "C inhibitor", 
      "unique biology", 
      "agents", 
      "current understanding", 
      "SummaryTreatment", 
      "pathophysiology", 
      "therapy", 
      "tebentafusp", 
      "subtypes", 
      "disease", 
      "trials", 
      "treatment", 
      "divergent responses", 
      "inhibitors", 
      "cells", 
      "review", 
      "options", 
      "response", 
      "management", 
      "near future", 
      "improvement", 
      "results", 
      "hope", 
      "purpose", 
      "novel approach", 
      "biology", 
      "understanding", 
      "approach", 
      "future", 
      "direction"
    ], 
    "name": "Novel Approaches to the Systemic Management of Uveal Melanoma", 
    "pagination": "104", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1129718020"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11912-020-00965-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32725406"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11912-020-00965-0", 
      "https://app.dimensions.ai/details/publication/pub.1129718020"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_846.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11912-020-00965-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11912-020-00965-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11912-020-00965-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11912-020-00965-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11912-020-00965-0'


 

This table displays all metadata directly associated to this object as RDF triples.

204 TRIPLES      21 PREDICATES      97 URIs      76 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11912-020-00965-0 schema:about N26307d8d1157444eb449b0aca0e0228d
2 N3ec2f9c628d64cb4a12296897709830c
3 N51732ed773cd4532a03cbcd16f8eb284
4 N88c9f0e7fcb744a7a41f00e2e45e1c2c
5 Na026751e840942f19c9748530d66ecae
6 Ne298b6d58c334b7e86025f9e4ec548df
7 Nf6070590a2c6433283e681cda629e583
8 anzsrc-for:11
9 anzsrc-for:1112
10 schema:author N92a77cdf7e6a45aabf9f75341af9fe84
11 schema:citation sg:pub.10.1007/s00262-019-02352-6
12 sg:pub.10.1007/s00347-006-1350-7
13 sg:pub.10.1007/s10555-017-9663-3
14 sg:pub.10.1007/s10555-018-9751-z
15 sg:pub.10.1038/bjc.1998.646
16 sg:pub.10.1038/nature07586
17 sg:pub.10.1038/nature09504
18 sg:pub.10.1038/ncomms10156
19 sg:pub.10.1038/ng.2523
20 sg:pub.10.1038/ng.3549
21 sg:pub.10.1038/s41467-018-04322-5
22 sg:pub.10.1038/s41588-019-0440-9
23 sg:pub.10.1186/s40425-019-0800-0
24 schema:datePublished 2020-07-28
25 schema:datePublishedReg 2020-07-28
26 schema:description Purpose of ReviewUveal melanoma is a distinct subtype of melanoma characterized by a unique biology and divergent response to immune therapies. In this review, we will discuss our current understanding of the pathophysiology of uveal melanoma, systemic treatment options for advanced disease, and potential future therapeutic directions.Recent FindingsAlthough treatment with single-agent checkpoint blockade has been generally disappointing, the results of combined checkpoint blockade are modestly more promising. Several alternative systemic therapeutic approaches have been or are currently being investigated, including two agents that have been taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor.SummaryTreatment of advanced uveal melanoma remains challenging, however, encouraging results from novel agents offer hope for improvement in the near future.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf N3ed185bc9e5244159315d72648a4be00
30 Nbf8236b091e24eaa9670ad154aa55f0f
31 sg:journal.1021174
32 schema:keywords C inhibitor
33 SummaryTreatment
34 T cells
35 advanced disease
36 advanced uveal melanoma
37 agents
38 approach
39 biology
40 blockade
41 cells
42 checkpoint blockade
43 clinical trials
44 current understanding
45 direction
46 disease
47 distinct subtypes
48 divergent responses
49 future
50 future therapeutic directions
51 hope
52 immune therapy
53 improvement
54 inhibitors
55 kinase C inhibitor
56 management
57 melanoma
58 near future
59 novel agents
60 novel approach
61 options
62 pathophysiology
63 potential future therapeutic directions
64 protein kinase C inhibitor
65 purpose
66 response
67 results
68 review
69 single-agent checkpoint blockade
70 subtypes
71 systemic management
72 systemic therapeutic approaches
73 systemic treatment options
74 tebentafusp
75 therapeutic approaches
76 therapeutic directions
77 therapy
78 treatment
79 treatment options
80 trials
81 understanding
82 unique biology
83 uveal melanoma
84 schema:name Novel Approaches to the Systemic Management of Uveal Melanoma
85 schema:pagination 104
86 schema:productId N05a1e0a10a81480caaea2b7014c80ecc
87 N45c8a6b45b754ddeb6c8963275e7d9fe
88 N7db160b3e14b44eb859d6f0bd1eb03aa
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1129718020
90 https://doi.org/10.1007/s11912-020-00965-0
91 schema:sdDatePublished 2022-12-01T06:41
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher N2840775e61ea4ab185dad7fac29a80a2
94 schema:url https://doi.org/10.1007/s11912-020-00965-0
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N05a1e0a10a81480caaea2b7014c80ecc schema:name pubmed_id
99 schema:value 32725406
100 rdf:type schema:PropertyValue
101 N137f807c559c4edf987e4ba7a2715718 rdf:first sg:person.0726366600.25
102 rdf:rest rdf:nil
103 N26307d8d1157444eb449b0aca0e0228d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Risk Assessment
105 rdf:type schema:DefinedTerm
106 N2840775e61ea4ab185dad7fac29a80a2 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 N3ec2f9c628d64cb4a12296897709830c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Humans
110 rdf:type schema:DefinedTerm
111 N3ed185bc9e5244159315d72648a4be00 schema:issueNumber 10
112 rdf:type schema:PublicationIssue
113 N45c8a6b45b754ddeb6c8963275e7d9fe schema:name doi
114 schema:value 10.1007/s11912-020-00965-0
115 rdf:type schema:PropertyValue
116 N51732ed773cd4532a03cbcd16f8eb284 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Prognosis
118 rdf:type schema:DefinedTerm
119 N7db160b3e14b44eb859d6f0bd1eb03aa schema:name dimensions_id
120 schema:value pub.1129718020
121 rdf:type schema:PropertyValue
122 N88c9f0e7fcb744a7a41f00e2e45e1c2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Antineoplastic Agents
124 rdf:type schema:DefinedTerm
125 N92a77cdf7e6a45aabf9f75341af9fe84 rdf:first sg:person.016242444426.32
126 rdf:rest N137f807c559c4edf987e4ba7a2715718
127 Na026751e840942f19c9748530d66ecae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Uveal Neoplasms
129 rdf:type schema:DefinedTerm
130 Nbf8236b091e24eaa9670ad154aa55f0f schema:volumeNumber 22
131 rdf:type schema:PublicationVolume
132 Ne298b6d58c334b7e86025f9e4ec548df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Melanoma
134 rdf:type schema:DefinedTerm
135 Nf6070590a2c6433283e681cda629e583 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Immunotherapy
137 rdf:type schema:DefinedTerm
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
142 schema:name Oncology and Carcinogenesis
143 rdf:type schema:DefinedTerm
144 sg:journal.1021174 schema:issn 1523-3790
145 1534-6269
146 schema:name Current Oncology Reports
147 schema:publisher Springer Nature
148 rdf:type schema:Periodical
149 sg:person.016242444426.32 schema:affiliation grid-institutes:grid.239585.0
150 schema:familyName Khan
151 schema:givenName Shaheer
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016242444426.32
153 rdf:type schema:Person
154 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.516091.a
155 schema:familyName Carvajal
156 schema:givenName Richard D.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
158 rdf:type schema:Person
159 sg:pub.10.1007/s00262-019-02352-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1116870697
160 https://doi.org/10.1007/s00262-019-02352-6
161 rdf:type schema:CreativeWork
162 sg:pub.10.1007/s00347-006-1350-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041025152
163 https://doi.org/10.1007/s00347-006-1350-7
164 rdf:type schema:CreativeWork
165 sg:pub.10.1007/s10555-017-9663-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083859374
166 https://doi.org/10.1007/s10555-017-9663-3
167 rdf:type schema:CreativeWork
168 sg:pub.10.1007/s10555-018-9751-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1106079214
169 https://doi.org/10.1007/s10555-018-9751-z
170 rdf:type schema:CreativeWork
171 sg:pub.10.1038/bjc.1998.646 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036277436
172 https://doi.org/10.1038/bjc.1998.646
173 rdf:type schema:CreativeWork
174 sg:pub.10.1038/nature07586 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018711414
175 https://doi.org/10.1038/nature07586
176 rdf:type schema:CreativeWork
177 sg:pub.10.1038/nature09504 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001851540
178 https://doi.org/10.1038/nature09504
179 rdf:type schema:CreativeWork
180 sg:pub.10.1038/ncomms10156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043043138
181 https://doi.org/10.1038/ncomms10156
182 rdf:type schema:CreativeWork
183 sg:pub.10.1038/ng.2523 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004149711
184 https://doi.org/10.1038/ng.2523
185 rdf:type schema:CreativeWork
186 sg:pub.10.1038/ng.3549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024973673
187 https://doi.org/10.1038/ng.3549
188 rdf:type schema:CreativeWork
189 sg:pub.10.1038/s41467-018-04322-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103889258
190 https://doi.org/10.1038/s41467-018-04322-5
191 rdf:type schema:CreativeWork
192 sg:pub.10.1038/s41588-019-0440-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117623763
193 https://doi.org/10.1038/s41588-019-0440-9
194 rdf:type schema:CreativeWork
195 sg:pub.10.1186/s40425-019-0800-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122559825
196 https://doi.org/10.1186/s40425-019-0800-0
197 rdf:type schema:CreativeWork
198 grid-institutes:grid.239585.0 schema:alternateName Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, 10032, New York, NY, USA
199 schema:name Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, 10032, New York, NY, USA
200 rdf:type schema:Organization
201 grid-institutes:grid.516091.a schema:alternateName Herbert Irving Comprehensive Cancer Center, New York, NY, USA
202 schema:name Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, 10032, New York, NY, USA
203 Herbert Irving Comprehensive Cancer Center, New York, NY, USA
204 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...